New drug that can extend the life of lung cancer patients made available in Wales

The drug has been proven to extend the life of lung cancer patients, with research showing that it significantly increases the number of patients still alive after three-years of treatment.

The drug is currently already available in Scotland and whilst the National Institute for Health and Care Excellence withheld the introduction of Nivolumab to NHS England because it was deemed too expensive, NICE approved the drug back in September.

The drug functions as a type of immunotherapy, interrupting the chemical signs that cancers use to convince the immune system tissue is healthy. It targets protein and is most effective when the patient has larger amounts of PD-L1 protein.

To see presentations of research transforming treatments in cancer, register for your free ticket to attend the European Oncology Convention here.

If you are interested in exhibiting to 2,000 senior decision makers from the top oncology hospitals and hospital departments in the world, actively looking to purchase products and services, please contact Nick Woore, Event Director, now on:

Tel: 0117 929 6097

Email: Nick.Woore@prysmgroup.co.uk